Tag Archives: orphan drug act

New Study Debunks Myths About Orphan Drug Act and Rare Disease Drug Costs

Be.Futureproof

The Orphan Drug Act has been targeted recently by the insurance industry and its allies in the media, but in the face of withering criticism and unjustified allegations, a new study from IMS Health shows that concerns about rare drug costs are completely misguided. Kaiser Health News’ Sarah Jane Tribble reports the study, published in Health Affairs, “analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

The Washington Post Unfairly Attacks The Orphan Drug Act

Greenwood_Jim_BTN

The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Complexities of Rare Diseases Take the Spotlight at BIO

Drugs

Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the challenges of rare diseases, but patients and their advocates aren’t always equipped to fight.” Organizations like Global Genes help families affected by rare disease by connecting them with much needed tools and resources. By better understanding the definition of a “rare” disease, industry Read More >

Business and Investments, Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Expanding Access to Orphan Drugs

Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,